Views & Analysis Going beyond CSR to reach ‘the two billion’ Impact of putting access to medicine at the core of pharma businesses.
Views & Analysis Outcomes-based medicine demands real-world evidence RWE must become a fundamental accompaniment to traditional RCT data.
Views & Analysis Effective decision making in early asset development and com... Addressing the data and evidence gap in the early stages of asset development.
Views & Analysis A novel UK approach to cancer access: yes, no, or maybe? Experts discuss the implications of the new, reinvigorated Cancer Drugs Fund, for pharma and patients.
Articles EFPIA’s director general, Richard Bergström, on market acces... He says the industry will partner with payers to deliver outcomes-driven, sustainable healthcare, in pharmaphorum's magazine Deep Dive: Market Access.
Views & Analysis New business models turn science into market value Delivering better patient benefit and economic returns.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
